<DOC>
	<DOCNO>NCT02322073</DOCNO>
	<brief_summary>Visceral obesity adipose inflammation consider drive force obesity-related systemic disease , e.g . liver cirrhosis chronic kidney disease ( CKD ) . Inflammatory resolution actively regulate specialized pro-resolving mediator ( SPMs ) , include endogenous eicosanoid LXA4 . Impairment SPMs may underlie development obesity-related pathology.We hypothesize obese patient develop obesity-related liver kidney disease suffer impair endogenous production pro-resolving lipid . This result aggravate adipose inflammation , cause systemic pathology kidney disease . We thus wish investigate adipose inflammation pro-resolving lipid profile obese subject without CKD liver disease . We also aim investigate whether LXA4 , LXB4 anti-inflammatory agent ( AICAR ) alter phenotype human adipose macrophage ex vivo tissue culture .</brief_summary>
	<brief_title>Inflammation Obesity-associated Disease</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Obese BMI 3555 kg/m2 Obese BMI 3555 kg/m2 + microalbuminuria Obese BMI 3555 kg/m2 + elevate ALT Lean BMI 18.524.9 Diabetes mellitus Medical treatment NSAIDs , TZDs , metformin insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>